On March 19, 2020, Akahoshi, Issei; Sumikawa, Yoshitake; Furuta, Sadayoshi; Fukushima, Keiichiro; Imazu, Takuya; Kotaka, Ryota published a patent.Quality Control of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Preparation of novel heteroaromatic amide derivatives and medicines containing them. And the patent contained the following:
The present invention provides novel heteroaromatic amide derivatives I [X1-X2 = N-C or C-N; Y1, Y2, Y3 and Y4 = independently single bond, -CH2-, -CR4aH-, CR4bH-, NR4c-, -O-, etc.; Z1 = single bond, -O-, -S-, etc.; ring A = a 3-7-membered monocyclic aromatic ring or an 8-12-membered bicyclic aromatic ring; R1a and R1b = H, halogen, alkyl, etc.; R2 = H, halogen, OH, etc.; R3a, R3b and R3c = independently H, halogen, CN, (un)substituted C1-6 alkyl, (un)substituted C1-6 haloalkyl, etc.; R4a, R4b, and R4c = independently (un)substituted C1-6 haloalkyl or C1-6 haloalkoxy, etc.; R5a = H, alkyl, etc.; R5b = H, alkyl, etc.; R5c = H, alkyl, etc.; R5a and R5b can join together to form -CH2O- or the like; R6a and R6b = independently H, halogen, alkyl, etc.; n = 1 or 2] and medicines containing them. For example, compound II (preparation given) was coupled with compound III to provide compound IV. The invention compounds selectively inhibit Nav1.7 rather than Nav1.5, and they are highly effective for various diseases associated with Nav1.7 such as pain. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Quality Control of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid
The Article related to heteroaromatic amide derivative preparation nav inhibitor pain treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Quality Control of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem